Tempus AI and AstraZeneca AB enter fifth amendment to master services agreement on Nov. 16
AZN•Tempus AI and AstraZeneca AB amended their master services agreement on Nov. 16, committing AstraZeneca to $200 million in fees over a five-year renewal period starting Jan. 1, 2027. The agreement runs through Dec. 31, 2031, and may extend by one year if the commitment is unmet.
1. Amended agreement
The amendment establishes a five-year financial commitment period beginning Jan. 1, 2027, and extends the master services agreement through Dec. 31, 2031. AstraZeneca committed to $200 million in aggregate fees, with an annual target spend of $40 million across Tempus AI products and services. AstraZeneca may terminate the agreement for convenience at any time; if the commitment is unmet by the end of the renewal term, the term extends through Dec. 31, 2032.




